This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

November 4–6, 2024Stockholm, Sweden

Daniel Steiners
Managing Director & General Manager Pharmaceutical Business Germany at Bayer Vital GmbH


Dr. Daniel Steiners has been Managing Director of Bayer Vital GmbH since April 2022. In this role, he is responsible for Bayer’s pharmaceutical business in Germany. Before moving back to Germany, Daniel was the general manager of Bayer Yakuhin’s Cardiovascular and Nephrology Business Unit in Osaka, Japan. Prior to moving to Japan, Daniel worked with Bayer in the USA where he gained first-hand experience in the US healthcare market. During his time in New Jersey, he has worked as a medical representative for Women’s Healthcare, the Market Access Brand Director for Bayer’s Hemophilia and Neurology franchise as well as the Head of Marketing for Bayer’s TKI Oncology franchise. Before moving to the US in 2016, Daniel was Head of Strategic Planning for Bayer HealthCare. Prior to that, he was Head of Corporate Strategy within Bayer AG’s Corporate Development department. Before joining Bayer in November 2009, Daniel was an Associate Principal with McKinsey & Company where he worked for clients in Europe, the USA and Russia. Daniel graduated from the University of Münster (Germany) with a master’s degree in business administration. He also earned a doctoral degree in management accounting from the European Business School in Oestrich-Winkel (Germany) and a Certificate in Health Sciences from the Open University (UK). Daniel is a certified systemic coach and change manager and has a passion for building and leading high performing cross-cultural and cross-functional teams that excel at providing innovative therapies to healthcare professionals and their patients

Agenda Sessions

  • The European pharmaceutical legislation – will it keep the light on for biotech in Europe ?